Evidence map›Paper›PMID 32766282›Full record

ArticleFrontiers in molecular biosciences2020

High-Throughput Screening of a Functional Human CXCL12-CXCR4 Signaling Axis in a Genetically Modified

James W Murphy, Deepa Rajasekaran, Janie Merkel, Erin Skeens, Camille Keeler, Michael E Hodsdon, George P Lisi, Elias Lolis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

James W MurphyDepartment of Pharmacology, Yale School of Medicine, Yale University, New Haven, CT, United States.
Deepa RajasekaranDepartment of Pharmacology, Yale School of Medicine, Yale University, New Haven, CT, United States.
Janie MerkelYale Center for Molecular Discovery, Yale School of Medicine, Yale University, New Haven, CT, United States.
Erin SkeensDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, United States.
Camille KeelerDepartment of Laboratory Medicine, Yale School of Medicine, Yale University, New Haven, CT, United States.
Michael E HodsdonDepartment of Laboratory Medicine, Yale School of Medicine, Yale University, New Haven, CT, United States.
George P LisiDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, RI, United States.
Elias LolisDepartment of Pharmacology, Yale School of Medicine, Yale University, New Haven, CT, United States.
Yale University · USBrown University · USYale Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CXCL12 activates CXCR4 and is involved in embryogenesis, hematopoiesis, and angiogenesis. It has pathological roles in HIV-1, WHIM disease, cancer, and autoimmune diseases. An antagonist, AMD3100, is used for the release of CD34+ hematopoietic stem cells from the bone marrow for autologous transplantation for lymphoma or multiple myeloma patients. Adverse effects are tolerated due to its short-term treatment, but AMD3100 is cardiotoxic in clinical studies for HIV-1. In an effort to determine whether

Indexed as

chemokineCXCL12CXCR4fosfosalG protein-coupled receptorhigh-throughput screeningNMR

Identifiers

PMID32766282
PMCPMC7378375
OpenAlexW3043642966

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.